27 citations
,
March 2017 in “Current Clinical Pharmacology” Dutasteride is becoming a popular hair loss treatment, proving more effective than finasteride with similar side effects.
March 2005 in “The Nurse Practitioner”
1 citations
,
January 2013 in “Hair therapy & transplantation” The document does not provide information about hair loss treatment.
October 2025 in “Figshare” Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.
January 2024 in “Scripta Medica” Nanoparticle delivery can reduce side effects of the cancer drug doxorubicin.
52 citations
,
January 2022 in “Current Research in Pharmacology and Drug Discovery” New treatments for COVID-19 show promise, but more effective antiviral drugs are needed.
CG2001 is safe, well-tolerated, and a promising treatment for hair loss with fewer side effects.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Baricitinib is widely used for several conditions, especially COVID-19, but its safety and effectiveness are still being evaluated.
14 citations
,
May 2008 in “Journal of proteome research” Dutasteride may help reduce brain plaque linked to Alzheimer's by affecting cell energy structures and waste removal.
September 2025 in “BMJ Case Reports” Platelet-rich plasma therapy may rarely trigger herpes zoster ophthalmicus.
March 2026 in “Journal of obstetrics and gynaecology research” Ark-e-Kasni improves PCOS symptoms and may be a potential treatment.
3 citations
,
January 2011 in “Yearbook of Dermatology and Dermatologic Surgery”
4 citations
,
September 2024 in “BMC Cancer” Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.
December 2024 in “International Journal of Scientific Reports” The plant-based hair serum is a promising and safe alternative to minoxidil for hair regrowth.
December 2020 in “Research Square (Research Square)” The AndroCoV Clinical Scoring is a quick, affordable, and accurate method for diagnosing COVID-19.
149 citations
,
April 2013 in “Drug Safety” Most severe COVID-19 patients had hair loss, suggesting a possible link.
June 2011 in “Oncology times” New treatments are making advanced prostate cancer management more complex but also more hopeful.
5 citations
,
December 2021 in “Journal of Cosmetic Dermatology” QR678 Neo® hair growth treatment is effective for hair loss caused by Covid-19.
October 2022 in “Amplla Editora eBooks” The document's conclusion cannot be provided because the content is not available for analysis.
29 citations
,
November 2021 in “FEBS Open Bio” Cepharanthine analogues, especially tetrandrine, show potential for treating COVID-19.
9 citations
,
October 2021 in “International Journal of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
February 1999 in “Drugs in R & D” The document concludes that various drugs for men's health issues are in development, with treatments for sexual dysfunction and prostate conditions being the most advanced.
June 2023 in “British journal of dermatology/British journal of dermatology, Supplement” Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.
12 citations
,
April 2023 in “Molecular Pharmaceutics” A new patch can deliver stable antibodies over time for potential HIV treatment.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Abatacept may help some people with alopecia areata regrow hair.
26 citations
,
August 2021 in “Medicine” Low testosterone and SHBG levels are linked to higher COVID-19 death rates.
August 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.
7 citations
,
December 2022 in “Skin Appendage Disorders” Certolizumab effectively treats psoriasis and psoriatic arthritis with fewer side effects than adalimumab.
Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might reduce it. AST decreases recurrence-free survival but doesn't affect overall survival or progression-free survival. More research is needed to understand AST's benefits.